STATEMENT: Verismo Therapeutics announces upcoming presentation at SITC 2023


STATEMENT: Verismo Therapeutics announces upcoming presentation at SITC 2023

PHILADELPHIA, Nov. 3, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing a novel KIR-CAR platform technology, today announced that it will be presenting at the upcoming 38th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2023), which will be held in San Diego and virtually from November 1 to 5, 2023.

Presentation details

Title: Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesotheliomaAbstract Number: 321Date and time: Friday, November 3: 12:00-1:30 p.m. and 5:10-6:40 p.m.Authors: Drs. Jun Xu, PhD

About the KIR-CAR Platform The KIR-CAR platform is a dual-chain CAR T cell therapy and has been shown in preclinical animal models to be able to maintain antitumor T cell activity even in difficult solid tumor environments. DAP12 acts as a novel T cell costimulatory molecule that utilizes additional T cell stimulation pathways, further maintaining chimeric receptor expression and improving functional persistence of KIR-CAR T cells. This continued T cell function and persistence may lead to continued regression of solid tumors in preclinical models, including those resistant to traditional CAR T cell therapies. The KIR-CAR platform is being investigated in combination with other emerging technologies.

About Verismo TherapeuticsVerismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, and its lead asset, SynKIR™-110, is in its first-in-human clinical trial. Verismo is the only company developing the KIR-CAR platform, a modified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors. The KIR-CAR platform technology was developed specifically for advanced solid tumors, an area of ​​high unmet medical need. For more information, visit:

Media Contact:

Gene KimVerismo TherapeuticsPR@verismotherapeutics.com215-989-4225

Jennifer MoritzZer0 to 5ivejmoritz@0to5.com917-748-4006

Logo -

View original content: